Results 31 to 40 of about 25,487 (238)

Serum Osteoprotegerin Level Is Negatively Associated with Bone Mineral Density in Patients Undergoing Maintenance Hemodialysis

Medicina, 2021
Background and Objectives: Osteoprotegerin (OPG), a potent osteoclast activation inhibitor, decreases bone resorption and plays a role in mediating bone mineral density (BMD).
Chia-Wen Lu, Chih-Hsien Wang, Bang-Gee Hsu, Jen-Pi Tsai   +3 more
doaj   +1 more source

The effect of osteoprotegerin on implant osseointegration in ovariectomized rats [PDF]

, 2017
Introduction : Osteoprotegerin (OPG), the endogenous inhibitor of RANKL, prevents or reverses bone loss in a variety of preclinical models of bone disease. Preclinical studies indicate that osteoporosis significantly impairs implant fixation.
Biao Liu, Yunfeng Li, Jing Hu, Yiming Liu, Xiliang Jiang   +4 more
core   +1 more source

Polymorphisms within RANKL and Osteoprotegerin Genes in Low Bone Mass among Postmenopausal Indonesian Women [PDF]

, 2019
Objective:Prior studies have shown that receptor activator of nuclear factor-B ligand (RANKL) and osteoprotegerin (OPG) have an essential role in bone remodeling and osteoporosis.
Herawati Sudoyo, Andri Lubis, Ambrosius Purba, Sri Widia Jusman, Murdani Abdullah, Ignatio Rika Haryono, Ermita Ibrahim Ilyas, Angela Tulaar   +7 more
core   +1 more source

Risk Factors Associated With Altered Circulating MicroRNA‐125b and Their Influences on Uremic Vascular Calcification Among Patients With End‐Stage Renal Disease

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019
Background MicroRNA‐125b (miR‐125b) has been shown to regulate vascular calcification (VC), and serum miR‐125b levels are a potential biomarker for estimating the risk of uremic VC status.
Chia‐Ter Chao, Tzu‐Hang Yuan, Hsiang‐Yuan Yeh, Hsuan‐Yu Chen, Jenq‐Wen Huang, Huei‐Wen Chen   +5 more
doaj   +1 more source

Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
Background Elevated levels of osteoprotegerin, a secreted tumor necrosis factor–related molecule, might be associated with adverse outcomes in patients with coronary artery disease. We measured plasma osteoprotegerin concentrations on hospital admission,
Thor Ueland, Axel Åkerblom, Tatevik Ghukasyan, Annika E. Michelsen, Pål Aukrust, Richard C. Becker, Maria Bertilsson, Anders Himmelmann, Stefan K. James, Agneta Siegbahn, Robert F. Storey, Frederic Kontny, Lars Wallentin   +12 more
doaj   +1 more source

Impact of Alirocumab on Release Markers of Atherosclerotic Plaque Vulnerability in Patients with Mixed Hyperlipidemia and Vulnerable Atherosclerotic Plaque

Medicina, 2022
Background and Objectives: Atherosclerosis is a disease in the pathogenesis of which plasma factors apart from elevated cholesterol levels play a keyrole. Such factors include osteopontin (OPN), osteoprotegerin (OPG), and metalloproteinases (MMPs), which
Michał Kosowski, Marcin Basiak, Marcin Hachuła, Bogusław Okopień   +3 more
doaj   +1 more source

High serum osteoprotegerin and low RANKL in primary biliary cirrhosis [PDF]

, 2003
Background/Aims: Osteoprotegerin is decoy receptor for osteoclast activating factor, RANKL, and impairs osteoclast funtion. Since osteoporosis is common in primary biliary cirrhosis (PBC), we investigated osteoprotegerin, RANKL and markers of bone ...
Dunkel, Kinga, Lakatos, Péter László, Szalay, Ferenc, Bajnok, Éva, Lakatos, Péter, Hegedűs, Dalma, Tornai, István   +6 more
core   +1 more source

Association of osteocalcin, osteoprotegerin, and osteopontin with cardiovascular disease and retinopathy in type 2 diabetes [PDF]

, 2023
Background: Novel biomarkers of vascular disease in diabetes could help identify new mechanistic pathways. Osteocalcin, osteoprotegerin, and osteopontin are key molecules involved in bone and vascular calcification processes, both of which are ...
Rury R. Holman, Lucia Coraggio, Morviducci, Lelio, Buzzetti, Raffaella, Ernesto Maddaloni, Pugliese, Giuseppe, Marco G. Baroni, Coraggio, Lucia, Napoli, Nicola, Maddaloni, Ernesto, Morano, Susanna, Giuseppe Pugliese, De Cosmo, Salvatore, Leonetti, Frida, Copetti, Massimiliano, Sentinelli, Federica, Cossu, Efisio, Rocco Amendolara, Nicola Napoli, D'Onofrio, Luca, Trischitta, Vincenzo, Massimiliano Copetti, Sabrina Prudente, Raffaella Buzzetti, D'Angelo, Paola, Luca D’Onofrio, Park, Kyoungmin, Susanna Morano, Baroni, Marco G, Paola D’Angelo, the SUMMER Study in Diabetes Group, Vincenzo Trischitta, Holman, Rury R, Frida Leonetti, Lelio Morviducci, Amendolara, Rocco, Efisio Cossu, Cosmo, Salvatore De, Maria G. Cavallo, Salvatore De Cosmo, Prudente, Sabrina, Kyoungmin Park, Cavallo, Maria G   +42 more
core   +1 more source

Osteoprotegerin, Rank and Rank Ligand [PDF]

, 2007
Osteoprotegerin, reseptör aktivatör nükleer kappa B ve reseptör aktivatör nükleer kappa B ligand’ın keşfi ve osteoklastojenezisteki rollerinin belirlenmesi kemik biyolojisinin anlaşılmasına çok önemli katkılar sağlamıştır.
Mehmetoğlu, İdris, Kurban, Sevil
core   +2 more sources

Endogenous Calcification Inhibitors in the Prevention of Vascular Calcification: A Consensus Statement From the COST Action EuroSoftCalcNet

Frontiers in Cardiovascular Medicine, 2019
The physicochemical deposition of calcium-phosphate in the arterial wall is prevented by calcification inhibitors. Studies in cohorts of patients with rare genetic diseases have shed light on the consequences of loss-of-function mutations for different ...
Magnus Bäck, Tamas Aranyi, M. Leonor Cancela, Miguel Carracedo, Natércia Conceição, Georges Leftheriotis, Vicky Macrae, Ludovic Martin, Yvonne Nitschke, Andreas Pasch, Daniela Quaglino, Frank Rutsch, Catherine Shanahan, Victor Sorribas, Flora Szeri, Flora Szeri, Pedro Valdivielso, Olivier Vanakker, Hervé Kempf   +18 more
doaj   +1 more source